Equities

ICON PLC

ICON PLC

Actions
Health CareMedical Equipment and Services
  • Price (USD)215.08
  • Today's Change2.32 / 1.09%
  • Shares traded1.17m
  • 1 Year change-20.90%
  • Beta1.2231
Data delayed at least 15 minutes, as of Nov 22 2024 17:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy6
Outperform10
Hold4
Sell0
Strong Sell0

Share price forecast in USD

The 17 analysts offering 12 month price targets for ICON PLC have a median target of 285.00, with a high estimate of 375.00 and a low estimate of 225.00. The median estimate represents a 33.95% increase from the last price of 212.76.
High76.3%375.00
Med34.0%285.00
Low5.8%225.00

Earnings history & estimates in USD

On Oct 23, 2024, ICON PLC reported 3rd quarter 2024 earnings of 3.35 per share.
The next earnings announcement is expected on Feb 19, 2025.
Average growth rate+0.63%
ICON PLC reported annual 2023 earnings of 12.79 per share on Jan 09, 2024.
Average growth rate+18.33%
More ▼

Revenue history & estimates in USD

ICON Public Limited Company had 3rd quarter 2024 revenues of 2.03bn. This missed the 2.13bn consensus estimate of the 15 analysts following the company. This was 2.60% above the prior year's 3rd quarter results.
Average growth rate-0.28%
ICON Public Limited Company had revenues for the full year 2023 of 8.12bn. This was 4.89% above the prior year's results.
Average growth rate+35.44%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.